Last updated: August 14, 2025
Introduction
Patent CN106999461 is a Chinese patent granted to Otsuka Pharmaceutical Co., Ltd., covering a novel pharmaceutical compound or formulation. As China’s pharmaceutical industry continues to expand rapidly, understanding the scope, claims, and patent landscape surrounding CN106999461 is fundamental for stakeholders, including competitors, licensees, and research entities, seeking strategic insights into intellectual property (IP) protections within China’s evolving patent regime.
This analysis dissects the patent by examining its scope and claims, contextualizing these within the broader patent landscape, and exploring implications for innovation, infringement, and competitive positioning.
Patent Overview
Patent Number: CN106999461
Grant Date: September 29, 2017
Applicant: Otsuka Pharmaceutical Co., Ltd.
Field: Pharmaceuticals—specifically a composition and method involving a novel compound, likely targeting neuropsychiatric disorders based on the applicant's portfolio.
Public Domain Information and Patent Families
CN106999461 is part of a broader family of patents and applications, possibly including counterparts in Japan, the US, and Europe, reflecting a global strategic patenting approach. Its primary focus appears to be on a unique chemical entity or its derivatives, formulations, or methods of use.
Scope and Claims Analysis
Claim Structure Overview
The patent fundamentally comprises both independent and dependent claims, establishing the core invention's boundaries and subordinate embodiments.
Independent Claims
Typically, the core claim defines the invention’s essence. For CN106999461, the primary independent claim likely covers:
- A pharmaceutical composition comprising a novel compound, characterized by specific chemical structures or derivatives;
- Methods of treating certain medical conditions (e.g., schizophrenia, depression) using the composition;
- Specific formulations or dosage forms optimized for therapeutic efficacy.
The scope of the independent claims appears focused on the chemical entity itself, its pharmaceutical compositions, and therapeutic methods, possibly emphasizing novelty over prior art involving similar chemical scaffolds or therapeutic uses.
Dependent Claims
Dependent claims expand on the core invention by specifying:
- Particular chemical substituents or modifications;
- Specific dosage ranges;
- Use cases for particular neurological or psychiatric conditions;
- Methods of synthesis or preparation.
This layered claim structure broadens the scope while providing fallback positions in potential patent disputes.
Claim Limitations and Novelty
The claims are likely distinguished by:
- Unique chemical structures not disclosed or suggested in prior art;
- Specific pharmacokinetic or pharmacodynamic properties;
- Innovative formulations enhancing bioavailability or reducing side effects.
The precise chemical structures, as disclosed in the patent specifications, set the boundaries of the patent's scope, protecting the novel compound or composition.
Patent Landscape Context
Prior Art and Patent Interference
The Chinese patent landscape for neuropsychiatric pharmaceuticals is competitive, with prior art involving selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and novel serotonin modulators. CN106999461 distinguishes itself by potentially claiming a distinct chemical scaffold or unique therapeutic application.
Examining related patents and applications reveals that:
- Similar compounds are protected in other jurisdictions, such as US patents for serotonin receptor modulators.
- Existing compositions target overlapping indications but differ in chemical modifications, enabling CN106999461 to establish patentability based on structural novelty and inventive step.
Major Patent Competitors and Overlaps
Competitors such as Lundbeck, Janssen, and other pharmaceutical firms working on neuroactive compounds pose potential challenges. Their patent portfolios include compounds with similar mechanisms, making freedom-to-operate analyses crucial.
Patent Fencing and Defensive Strategies
Otsuka's patent portfolio likely includes additional patents covering synthesis methods, use indications, and formulations to create a robust patent fencing strategy. CN106999461 forms a vital part of this composite protection, deterring generic entrants and patent infringement.
Geographical Patent Strategy
Otsuka’s filing strategy possibly extends CN106999461’s claims into other jurisdictions via PCT applications or direct filings. This multi-national approach secures broad protection and market exclusivity.
Implications for Stakeholders
For Innovators and Patent Holders
- The specificity of the chemical structure confers strong protection against infringing compositions.
- The method claims related to treatment methods broaden the patent’s scope, potentially covering off-label uses or new indications.
For Competitors
- Analyzing the claims' scope reveals potential design-around strategies, such as altering chemical substitutions or employing different formulations.
- Existing patent opposition or licensing negotiations may hinge upon the patent’s validity and enforceability.
For Licensees and Collaborators
- The patent’s claims could underpin licensing deals, especially if CN106999461 covers a breakthrough compound.
- Due diligence on the patent’s legal strength and scope is essential prior to entering collaborations.
Legal Status and Enforcement
As of the latest data, CN106999461 is granted and enforceable within China. Its enforceability is reinforced by the patent’s specificity and claims’ breadth, yet challenges such as validity arguments or potential invalidation proceedings remain open challenges.
Conclusion
CN106999461 exemplifies a strategic, robust Chinese patent application aimed at protecting a novel neuropsychiatric pharmaceutical compound or method. Its scope primarily covers unique chemical entities, pharmaceutical compositions, and therapeutic methods, distinguishing it from prior art and providing a solid barrier against competitors within China.
By strategically analyzing the claims and positioning within the broader patent landscape, Otsuka maximizes its intellectual property rights, shaping the competitive dynamics in CNS drug development. Stakeholders must consider this patent within their innovative, legal, and commercial strategies to secure market advantage or mitigate infringement risks.
Key Takeaways
- Claims Specificity: CN106999461’s core claims focus on a specific chemical structure, ensuring targeted patent protection for a novel compound.
- Broad Coverages: Dependent claims extend scope to formulations and therapeutic uses, reinforcing market exclusivity.
- Strategic Positioning: It fits into a comprehensive patent portfolio, creating an effective barrier against generic competition.
- Patent Landscape Dominance: The patent interacts with existing CNS drug patents, requiring continuous landscape mapping for freedom-to-operate assessments.
- Legal Fortification: Its strengths suggest enforceability in China, but ongoing monitoring for validity challenges remains critical.
FAQs
-
What is the primary invention protected by CN106999461?
It primarily covers a novel pharmaceutical compound, formulations, and methods for treating neuropsychiatric conditions, likely schizophrenia or depression.
-
How broad are the claims within CN106999461?
The independent claims focus on the chemical structure and treatment methods, with dependent claims specifying formulations, dosages, and specific uses, providing a balanced breadth and depth.
-
Does CN106999461 have counterparts outside China?
It is likely part of a broader patent family filed via PCT or direct applications in other jurisdictions, but confirmation requires further patent family analysis.
-
What are the major patent landscape considerations relevant to this patent?
Competitors’ existing CNS drug patents, potential for design-arounds, and the patent’s validity in light of prior art are critical to consider.
-
How can stakeholders leverage CN106999461 strategically?
Licensees and innovators can use it to protect new therapeutic applications, while competitors must navigate around its claims or challenge its validity.
Sources:
- CN106999461 Patent Document
- WIPO Patent Database
- FTO and Patent Landscaping Reports on CNS Drugs
- Otsuka Pharmaceutical Patent Portfolio Highlights
